公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2015 | A randomized Phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib maintenance (PC/G) with gefitinib monotherapy (G) in East Asian patients (pts) with locally advanced or metastatic nonsquamous non-small cell lung cancer (nSqNSCLC): Final survival results. | Yang, James Chih-Hsin; Srimuninnimit, Vichien; Ahn, Myung-Ju; Lin, Chia-Chi; Kim, Sang-We; Tsai, Chun-Ming; Mok, Tony; Orlando, Mauro; Puri, Tarun; Wang, Xin; Park, Keunchil | J. Clin. Oncol. | | | |
2023 | Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial | Chmielecki, Juliann; Mok, Tony; Wu, Yi-Long; Han, Ji-Youn; Ahn, Myung-Ju; Ramalingam, Suresh S; John, Thomas; Okamoto, Isamu; CHIH-HSIN YANG ; Shepherd, Frances A; Bulusu, Krishna C; Laus, Gianluca; Collins, Barbara; Barrett, J Carl; Hartmaier, Ryan J; Papadimitrakopoulou, Vassiliki | Nature communications | 21 | 16 | |
2023 | Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC | Zhou, Qing; Soo, Ross A; Chang, Gee-Chen; Chiu, Chao-Hua; Hayashi, Hidetoshi; Kim, Sang-We; Teraoka, Shunsuke; Goto, Yasushi; Zhou, Jianying; Ho-Fun Lee, Victor; Kim, Dong-Wan; Han, Baohui; Chung Man Ho, James; CHIA-CHI LIN ; Lu, Shun; Polli, Anna; Calella, Anna Maria; Martini, Jean-François; Wong, Chew Hooi; Mok, Tony; Kim, Hye Ryun; Wu, Yi-Long | JTO clinical and research reports | 3 | 0 | |
2022 | Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy | Lau, George; Yu, Ming-Lung; Wong, Grace; Thompson, Alexander; Ghazinian, Hasmik; Hou, Jin-Lin; Piratvisuth, Teerha; Jia, Ji-Dong; Mizokami, Masashi; Cheng, Gregory; Chen, Guo-Feng; Liu, Zhen-Wen; Baatarkhuu, Oidov; ANN-LII CHENG ; Ng, Woon Leung; Lau, Patrick; Mok, Tony; Chang, Jer-Ming; Hamid, Saeed; Dokmeci, A Kadir; Gani, Rino A; Payawal, Diana A; Chow, Pierce; Park, Joong-Won; Strasser, Simone I; Mohamed, Rosmawaiti; Win, Khin Maung; Tanwandee, Tawesak; Sarin, Shiv Kumar; Omata, Masao | Hepatology international | 0 | 0 | |
2023 | Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia | Mitsudomi, Tetsuya; Tan, Daniel; CHIH-HSIN YANG ; Ahn, Myung-Ju; Batra, Ullas; Cho, Byoung-Chul; Cornelio, Gerardo; Lim, Tony; Mok, Tony; Prabhash, Kumar; Reungwetwattana, Thanyanan; Ren, Sheng-Xiang; Singh, Navneet; Toyooka, Shinichi; Wu, Yi-Long; PAN-CHYR YANG ; Yatabe, Yasushi | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 13 | 12 | |
2017 | Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer | Blackhall, Fiona; Ross Camidge, D; Shaw, Alice T; Soria, Jean-Charles; Solomon, Benjamin J; Mok, Tony; Hirsh, Vera; Jänne, Pasi A; Shi, Yuankai; PAN-CHYR YANG ; Pas, Tommaso De; Hida, Toyoaki; Carpeño, Javier De Castro; Lanzalone, Silvana; Polli, Anna; Iyer, Shrividya; Reisman, Arlene; Wilner, Keith D; Kim, Dong-Wan | ESMO open | 84 | 68 | |
2015 | Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC). | Yang, James Chih-Hsin; Ahn, Myung-Ju; Dickgreber, Nicolas J.; Halmos, Balazs; Hirsh, Vera; Hochmair, Maximilian J.; Levy, Benjamin Philip; De Marinis, Filippo; Mok, Tony; O'Byrne, Kenneth; Okamoto, Isamu; Schuler, Martin H.; Sebastian, Martin; Shah, Riyaz N. H.; Tan, Eng-Huat; Yamamoto, Nobuyuki; Marten, Angela; Massey, Dan; Wind, Sven; Carbone, David Paul | J. Clin. Oncol. | | | |
2023 | Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations | Sequist, Lecia V; CHIH-HSIN YANG ; Yamamoto, Nobuyuki; O'Byrne, Kenneth; Hirsh, Vera; Mok, Tony; Geater, Sarayut Lucien; Orlov, Sergey; Tsai, Chun-Ming; Boyer, Michael; Su, Wu-Chou; Bennouna, Jaafar; Kato, Terufumi; Gorbunova, Vera; Lee, Ki Hyeong; Shah, Riyaz; Massey, Dan; Zazulina, Victoria; Shahidi, Mehdi; Schuler, Martin | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 7 | 34 | |
2012 | A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II | Mok, Tony; Wu, Yi Long; Thongprasert, Sumitra; Yu, Chong-Jen; Zhang, Li; Ladrera, Guia Elena; Srimuninnimit, Vichien; Sriuranpong, Virote; Sandoval-Tan, Jennifer; Zhu, Yunzhong; Liao, Meilin; Zhou, Caicun; Pan, Hongming; Lee, Victor; Chen, Yuh-Min; Sun, Yan; Margono, Benjamin; Jin, Kate; Truman, Matt; Lee, Jin Soo; 余忠仁 | J. Clin. Oncol. | | | |
2015 | The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials. | Lee, Chee; Davies, Lucy Claire; Wu, Yi-Long; Mitsudomi, Tetsuya; Inoue, Akira; Rosell, Rafael; Zhou, Caicun; Nakagawa, Kazuhiko; Throngprasert, Sumitra; Fukuoka, Masahiro; Gralla, Richard J.; Gebski, Val; Mok, Tony; Yang, James Chih-Hsin | J. Clin. Oncol. | | | |
2015 | TIGER-1: A Phase 2/3 Study of First Line Rociletinib or Erlotinib in EGFR-Mutant NSCLC | Camidge, Ross; Cappuzzo, Federico; Go, Jowell; Isaacson, Jeffrey; Litten, Jason; Park, Keunchil; Spigel, David R.; Spira, Alexander; Vergnenegre, Alain; Wolf, Juergen; Yang, James Chih-Hsin; Mok, Tony | J. Thorac. Oncol. | | | |